VTAMA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VTAMA (VTAMA).
VTAMA (tapinarof) is an aryl hydrocarbon receptor (AhR) agonist. It modulates the activity of AhR, leading to regulation of cytokines and inflammatory mediators involved in psoriasis pathogenesis, including suppression of IL-17 and IL-23 pathways, and promotion of skin barrier repair.
| Metabolism | Tapinarof undergoes extensive hepatic metabolism via CYP1A1, CYP1A2, and CYP2C9, as well as direct glucuronidation by UGT1A1 and UGT1A3. |
| Excretion | Following topical application of VTAMA (tapinarof) cream, 1%, systemic absorption is minimal. Unabsorbed drug is primarily eliminated via fecal excretion (estimated >99% of applied dose remains on skin or is washed off). Following intravenous administration in animal studies, tapinarof is extensively metabolized and excreted in bile/feces; renal excretion of unchanged drug is negligible (<2%). |
| Half-life | Tapinarof has a terminal elimination half-life of approximately 20 hours in the systemic circulation. Due to minimal systemic absorption after topical application, this half-life is relevant only for the small amount of drug that reaches the bloodstream. The half-life supports once-daily topical dosing without systemic accumulation. |
| Protein binding | Tapinarof is >99% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Due to minimal systemic absorption after topical administration, the clinical volume of distribution (Vd) is not well defined. Based on intravenous data in animals, Vd is approximately 0.2 L/kg, suggesting distribution mainly into plasma and interstitial fluid. |
| Bioavailability | Systemic bioavailability following topical application of tapinarof cream, 1%, is negligible (<1% of applied dose) as determined by plasma concentrations below the limit of quantification in most patients after multiple doses. |
| Onset of Action | Clinical improvement (reduction in plaque psoriasis severity) is typically observed within 4 to 8 weeks of once-daily topical application. Some patients may note early changes by week 2, but full onset is assessed at 8–12 weeks. |
| Duration of Action | Sustained effect is maintained with continuous once-daily application. After discontinuation, disease control may persist for several weeks before relapse. Based on clinical trials, the effect lasts as long as treatment continues; no formal duration after cessation has been established. |
Apply a thin layer to affected areas once daily. For topical use only. Not for ophthalmic, oral, or intravaginal use.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. |
| Geriatric use | No specific dose adjustment is recommended for elderly patients; however, caution is advised due to potential increased skin sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VTAMA (VTAMA).
| Breastfeeding | It is unknown whether tapinarof is excreted in human milk. Following topical application, systemic absorption is minimal (<1%), so the amount present in milk is likely negligible. The M/P ratio has not been determined. Caution should be exercised, though the risk to the nursing infant is considered low. |
| Teratogenic Risk | Teratogenic risk profile for tapinarof (VTAMA) during pregnancy is not established due to insufficient human data. In animal studies, no evidence of teratogenicity was observed at systemic exposures up to 13 times the maximum recommended human dose (MRHD) based on AUC. However, because systemic absorption after topical application is minimal (<1%), the risk is expected to be low. No specific trimester risks can be delineated. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to tapinarof or any component of the formulation."]
| Precautions | ["Local skin reactions (e.g., folliculitis, pruritus, contact dermatitis) were observed in clinical trials. Not for oral, ophthalmic, or intravaginal use. Patients should be advised to report signs of skin infection or severe irritation."] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care. However, as with any topical medication, avoid application to large areas of damaged skin or occlusive dressings to minimize systemic absorption. |
| Fertility Effects | In animal studies, no adverse effects on fertility or reproductive performance were observed at systemic exposures up to 13 times the MRHD. Human data are lacking, but due to minimal systemic absorption after topical use, fertility effects are unlikely. |